|
US5437291A
(en)
|
1993-08-26 |
1995-08-01 |
Univ Johns Hopkins |
Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
|
|
US6974578B1
(en)
|
1993-12-28 |
2005-12-13 |
Allergan, Inc. |
Method for treating secretions and glands using botulinum toxin
|
|
US5766605A
(en)
|
1994-04-15 |
1998-06-16 |
Mount Sinai School Of Medicine Of The City University Of New York |
Treatment of autonomic nerve dysfunction with botulinum toxin
|
|
US5670484A
(en)
|
1994-05-09 |
1997-09-23 |
Binder; William J. |
Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
|
|
AU2431995A
(en)
*
|
1994-05-09 |
1995-11-29 |
William J. Binder |
Method for reduction of headache pain
|
|
US6063768A
(en)
|
1997-09-04 |
2000-05-16 |
First; Eric R. |
Application of botulinum toxin to the management of neurogenic inflammatory disorders
|
|
US6265379B1
(en)
|
1999-10-13 |
2001-07-24 |
Allergan Sales, Inc. |
Method for treating otic disorders
|
|
US6139845A
(en)
|
1999-12-07 |
2000-10-31 |
Allergan Sales, Inc. |
Method for treating cancer with a neurotoxin
|
|
US20060269575A1
(en)
*
|
2000-02-08 |
2006-11-30 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
|
|
US8632785B2
(en)
*
|
2000-02-08 |
2014-01-21 |
Allergan, Inc. |
Clostridial toxin pharmaceutical composition containing a gelatin fragment
|
|
US7780967B2
(en)
*
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
US6464986B1
(en)
|
2000-04-14 |
2002-10-15 |
Allegan Sales, Inc. |
Method for treating pain by peripheral administration of a neurotoxin
|
|
US6299893B1
(en)
|
2000-04-17 |
2001-10-09 |
Marvin Schwartz |
Method to reduce hair loss and stimulate hair regrowth
|
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US6423319B1
(en)
|
2000-10-04 |
2002-07-23 |
Allergan Sales, Inc. |
Methods for treating muscle injuries
|
|
US7226605B2
(en)
|
2001-07-27 |
2007-06-05 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Botulinum toxin in the treatment or prevention of acne
|
|
MXPA01011542A
(es)
*
|
2001-11-13 |
2003-05-22 |
Alcon Inc |
Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
|
|
US7691394B2
(en)
*
|
2002-05-28 |
2010-04-06 |
Botulinum Toxin Research Associates, Inc. |
High-potency botulinum toxin formulations
|
|
US7459164B2
(en)
|
2002-05-28 |
2008-12-02 |
Botulinum Toxin Research Associates, Inc. |
Composition for therapeutic and cosmetic botulinum toxin
|
|
AU2003231878A1
(en)
|
2002-05-31 |
2003-12-19 |
Solux Corporation |
Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
|
|
JP2006519761A
(ja)
*
|
2002-12-20 |
2006-08-31 |
ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド |
改善された薬学的ボツリヌス毒素組成物
|
|
US7396535B2
(en)
*
|
2003-04-25 |
2008-07-08 |
Ackerman Alan H |
Therapy for obsessive compulsive head banging
|
|
DE10333317A1
(de)
*
|
2003-07-22 |
2005-02-17 |
Biotecon Therapeutics Gmbh |
Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
|
|
US7160699B2
(en)
*
|
2003-09-25 |
2007-01-09 |
Allergan, Inc. |
Media for clostridium bacterium and processes for obtaining a clostridial toxin
|
|
US9078892B2
(en)
*
|
2004-02-26 |
2015-07-14 |
Allergan, Inc. |
Methods for treating pain and for treating a medication overuse disorder
|
|
US20100266638A1
(en)
*
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
|
US20050191321A1
(en)
*
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
|
GB2416122A
(en)
|
2004-07-12 |
2006-01-18 |
Ipsen Ltd |
Botulinum neurotoxin composition
|
|
KR100852821B1
(ko)
*
|
2004-07-26 |
2008-08-18 |
메르츠 파마 게엠베하 운트 코. 카가아 |
보툴리눔 신경독소를 포함하는 치료 조성물
|
|
DK1776137T3
(en)
*
|
2004-08-04 |
2015-01-05 |
Ipsen Biopharm Ltd |
A pharmaceutical composition comprising botulinum neurotoxin A2
|
|
US20060073208A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Allergan, Inc. |
Cosmetic neurotoxin compositions and methods
|
|
DK1853623T3
(da)
*
|
2005-03-03 |
2013-07-15 |
Allergan Inc |
Dyreprodukt-frit system og fremgangsmåde til oprensning af et botulinumtoksin
|
|
US20090214466A1
(en)
*
|
2005-05-09 |
2009-08-27 |
Levin Bruce H |
Methods of Alleviating Disorders and Their Associated Pain
|
|
US8926991B2
(en)
*
|
2005-06-14 |
2015-01-06 |
Botulinum Toxin Research Associates, Inc. |
Botulinum toxin and the treatment of primary disorders of mood and affect
|
|
US8323666B2
(en)
*
|
2005-08-01 |
2012-12-04 |
Allergan, Inc. |
Botulinum toxin compositions
|
|
US7744904B1
(en)
*
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
|
US8137677B2
(en)
*
|
2005-10-06 |
2012-03-20 |
Allergan, Inc. |
Non-protein stabilized clostridial toxin pharmaceutical compositions
|
|
US8168206B1
(en)
*
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
WO2007044809A2
(en)
*
|
2005-10-11 |
2007-04-19 |
Botulinum Toxin Research Associates, Inc. |
Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
|
|
US9061025B2
(en)
*
|
2006-08-31 |
2015-06-23 |
Allergan, Inc. |
Methods for selecting headache patients responsive to botulinum toxin therapy
|
|
FR2910327B1
(fr)
|
2006-12-22 |
2013-04-26 |
Scras |
Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
|
|
CN101687046B
(zh)
|
2007-07-10 |
2012-12-26 |
株式会社美地拓斯 |
稳定性改善的肉毒毒素药物液体组合物
|
|
US9161970B2
(en)
*
|
2007-12-12 |
2015-10-20 |
Allergan, Inc. |
Dermal filler
|
|
US9044477B2
(en)
*
|
2007-12-12 |
2015-06-02 |
Allergan, Inc. |
Botulinum toxin formulation
|
|
EP2072039A1
(en)
*
|
2007-12-21 |
2009-06-24 |
Merz Pharma GmbH & Co.KGaA |
Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
|
|
US9107815B2
(en)
*
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
|
US8617571B2
(en)
*
|
2008-04-03 |
2013-12-31 |
Allergan, Inc. |
Suture line administration technique using botulinum toxin
|
|
KR20090120222A
(ko)
*
|
2008-05-19 |
2009-11-24 |
(주)메디톡스 |
식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
|
|
US8535276B2
(en)
*
|
2008-06-26 |
2013-09-17 |
Bellanovus Development Company Llc |
Syringe-attached topical anesthetic dispenser
|
|
WO2010096134A1
(en)
*
|
2008-12-04 |
2010-08-26 |
Botulinum Toxin Research Associates, Inc. |
Extended length botulinum toxin formulation for human or mammalian use
|
|
JP2012512162A
(ja)
|
2008-12-10 |
2012-05-31 |
アラーガン、インコーポレイテッド |
クロストリジウム毒素医薬組成物
|
|
KR102363878B1
(ko)
*
|
2008-12-31 |
2022-02-16 |
레반스 테라퓨틱스, 아이엔씨. |
주사용 보툴리눔 독소 제제
|
|
ES2538835T3
(es)
|
2009-01-07 |
2015-06-24 |
Robert John Petrella |
Tratamiento de lesiones de tejidos blandos utilizando el ácido hialurónico y la toxina botulínica
|
|
EP2248518B1
(en)
*
|
2009-04-17 |
2013-01-16 |
Merz Pharma GmbH & Co. KGaA |
Formulation for stabilizing proteins, peptides or mixtures thereof.
|
|
KR101453601B1
(ko)
|
2009-05-29 |
2014-10-22 |
갈데르마 리써어치 앤드 디벨로프먼트 |
주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
|
|
EP2445521A4
(en)
*
|
2009-06-25 |
2015-08-26 |
Revance Therapeutics Inc |
ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
|
|
KR101736775B1
(ko)
*
|
2009-06-30 |
2017-05-18 |
(주)아모레퍼시픽 |
복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물
|
|
US8129139B2
(en)
*
|
2009-07-13 |
2012-03-06 |
Allergan, Inc. |
Process for obtaining botulinum neurotoxin
|
|
LT2490986T
(lt)
|
2009-10-21 |
2018-11-26 |
Revance Therapeutics, Inc. |
Nekompleksinio botulino neurotoksino gryninimo būdai ir sistemos
|
|
US20120238969A1
(en)
*
|
2009-10-30 |
2012-09-20 |
Revance Therapeutics, Inc |
Device and Method for Topical Application of Therapeutics or Cosmetic Compositions
|
|
WO2011075623A1
(en)
*
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
US8940308B2
(en)
*
|
2010-03-30 |
2015-01-27 |
Allergan, Inc. |
Methods for treating depression
|
|
AU2011316111B2
(en)
*
|
2010-10-12 |
2015-05-28 |
Merz Pharma Gmbh & Co. Kgaa |
Formulation suitable for stabilizing proteins, which is free of mammalian excipients
|
|
PH12013502022B1
(en)
*
|
2011-03-31 |
2018-12-12 |
Medy Tox Inc |
Lyophilized preparation of botulinum toxin
|
|
KR20130022923A
(ko)
*
|
2011-08-26 |
2013-03-07 |
삼성전자주식회사 |
가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
|
|
DK3130347T3
(da)
*
|
2011-12-30 |
2019-10-14 |
Halozyme Inc |
PH20-polypeptidvarianter, formuleringer og anvendelser deraf
|
|
AU2013243955B2
(en)
*
|
2012-04-02 |
2018-02-22 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9480731B2
(en)
*
|
2013-12-12 |
2016-11-01 |
Medy-Tox, Inc. |
Long lasting effect of new botulinum toxin formulations
|
|
EP3109609B1
(en)
|
2014-03-18 |
2020-10-21 |
Hitachi Metals, Ltd. |
Electroconductive resin composition and pressure sensor
|
|
US9579502B2
(en)
*
|
2014-04-19 |
2017-02-28 |
Medtronic, Inc. |
Implantable medical leads, systems, and related methods for creating a high impedance within a conduction path in the presence of a magnetic field of a given strength
|
|
CN108136038A
(zh)
*
|
2015-11-25 |
2018-06-08 |
乐高化学生物科学股份有限公司 |
包含肽基团的缀合物及其相关方法
|
|
WO2017203038A1
(en)
|
2016-05-27 |
2017-11-30 |
Ipsen Biopharm Limited |
Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
|
|
WO2018038301A1
(en)
|
2016-08-26 |
2018-03-01 |
Hugel Inc. |
Stabilized liquid formulation of botulinum toxin and preparation method thereof
|
|
KR102463881B1
(ko)
*
|
2016-10-04 |
2022-11-07 |
(주)메디톡스 |
보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
|
|
KR102088104B1
(ko)
*
|
2018-06-29 |
2020-03-11 |
호서대학교 산학협력단 |
개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
|
|
EP3849512A1
(en)
*
|
2018-09-13 |
2021-07-21 |
Allergan, Inc. |
Clostridial toxin-hyaluronic acid compositions
|
|
KR101968873B1
(ko)
*
|
2018-09-21 |
2019-04-29 |
아이큐어 주식회사 |
세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
|
|
UY38744A
(es)
|
2019-06-07 |
2020-12-31 |
Nestle Skin Health S A |
Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
|